Rajeev Suri - Stryker Independent Director
| SYK Stock | USD 327.45 8.58 2.55% |
Director
Mr. Rajeev Suri is Independent Director of the Company. He is President and Chief Executive Officer of Nokia, a leading global technology company, since April 2014. From 2009 to 2014, he was Chief Executive Officer of Nokia Solutions and Networks . Much of his nearly 30year career was spent in leadership roles at Nokia. He is also a United Nations Broadband Commissioner and a member of the steering committee of the Digital Communications Industry at the World Economic Forum since 2018.
| Age | 53 |
| Tenure | 6 years |
| Address | 1941 Stryker Way, Portage, MI, United States, 49002 |
| Phone | 269 385 2600 |
| Web | https://www.stryker.com |
Stryker Management Efficiency
The company has Return on Asset of 0.0687 % which means that on every $100 spent on assets, it made $0.0687 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1798 %, implying that it generated $0.1798 on every 100 dollars invested. Stryker's management efficiency ratios could be used to measure how well Stryker manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Stryker's Return On Capital Employed is quite stable compared to the past year. Return On Assets is expected to rise to 0.11 this year, although the value of Return On Tangible Assets will most likely fall to 0.10. At this time, Stryker's Total Current Liabilities is quite stable compared to the past year. Liabilities And Stockholders Equity is expected to rise to about 41.9 B this year, although the value of Non Current Liabilities Other will most likely fall to about 1.8 B.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Craig Thompson | Charles River Laboratories | 64 | |
| John Thompson | Illumina | 68 | |
| Laurie Glimcher | Waters | 66 | |
| Robert Herbold | Agilent Technologies | 74 | |
| Susan Siegel | Illumina | 57 | |
| Tyler Jacks | Thermo Fisher Scientific | 59 | |
| George Llado | Charles River Laboratories | 55 | |
| Caroline Dorsa | Illumina | 58 | |
| George Milne | Charles River Laboratories | 77 | |
| Hans Bishop | Agilent Technologies | 56 | |
| Martin Harris | Thermo Fisher Scientific | 61 | |
| Stanley Meresman | Guardant Health | 71 | |
| Ian Clark | Guardant Health | 57 | |
| Thomas Salice | Mettler Toledo International | 61 | |
| Richard Reese | Charles River Laboratories | 75 | |
| George Scangos | Agilent Technologies | 72 | |
| Arthur Bowman | Illumina | 69 | |
| Deborah Kochevar | Charles River Laboratories | 64 | |
| Hans Maerki | Mettler Toledo International | 71 | |
| R Keith | Thermo Fisher Scientific | 52 | |
| Rebecca Chambers | Illumina | N/A | |
Management Performance
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0687 |
Stryker Leadership Team
Elected by the shareholders, the Stryker's board of directors comprises two types of representatives: Stryker inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Stryker. The board's role is to monitor Stryker's management team and ensure that shareholders' interests are well served. Stryker's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Stryker's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Donald Payerle, President Replacement | ||
| Lisa Tatum, Independent Director | ||
| Ronda Stryker, Independent Director | ||
| Preston Wells, Vice President - Investor Relations | ||
| Ramesh Subrahmanian, Advisor | ||
| Bradford Saar, President Medical | ||
| Spencer Stiles, Group President Orthopaedics and Spine | ||
| William Berry, Principal Accounting Officer, Vice President, Corporate Controller | ||
| Katherine Owen, Vice President - Strategy and Investor Relations | ||
| Dragana Bunjevac, Middle Europe | ||
| Giovanni Caforio, Independent Director | ||
| Jason Beach, Vice Relations | ||
| Roch Doliveux, Independent Director | ||
| William Jellison, CFO and VP | ||
| Yin Becker, Vice President - Communications, Public Affairs and Corporate Marketing | ||
| M Fink, Chief Human Resource Officer, Vice President | ||
| Dylan Crotty, President Instruments | ||
| Dean Bergy, VP and Corporate Secretary | ||
| Alan Douville, Chief VP | ||
| Glenn Boehnlein, Chief Financial Officer, Vice President | ||
| J Pierce, Group President MedSurg and Neurotechnology | ||
| Mary Brainerd, Independent Director | ||
| Srikant Datar, Independent Director | ||
| Maurice BenMayor, President Pacific | ||
| Michael Hutchinson, General Counsel | ||
| Howard Cox, Independent Director | ||
| Kathryn Fink, Chief Human Resource Officer, Vice President | ||
| Scott Bruder, Vice President Chief Medical and Scientific Officer | ||
| Andrew Silvernail, Independent Director | ||
| Fink, Vice President Global Human Resources | ||
| Sherilyn McCoy, Independent Director | ||
| Robert Cohen, CTO Replacement | ||
| Curtis Hall, Chief Legal Officer | ||
| Andrew Pierce, Group Neurotechnology | ||
| Allan Golston, Lead Independent Director | ||
| Graham Mclean, President Asia-Pacific | ||
| Stuart Silk, Middle Europe | ||
| Louise Francesconi, Independent Director | ||
| Kevin Lobo, Chairman of the Board, President, Chief Executive Officer | ||
| David Floyd, Group President of Orthopaedics | ||
| Mike Panos, North RD | ||
| Timothy Scannell, Group President of Medsurg and Neurotechnology | ||
| William Parfet, Non-Executive Independent Chairman of the Board | ||
| Robert Fletcher, Vice President Chief Legal Officer | ||
| Brian White, President Solutions | ||
| Brent Ladd, President Endoscopy | ||
| Rajeev Suri, Independent Director | ||
| Viju Menon, Group President - Global Quality and Business Operations | ||
| Lonny Carpenter, Group President - Global Quality and Operations | ||
| Bijoy Sagar, Chief Digital Technology Officer, Vice President | ||
| Bronwen Taylor, Vice President - Compliance and Risk Management | ||
| Steven Benscoter, Vice President - Human Resources |
Stryker Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Stryker a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.18 | ||||
| Return On Asset | 0.0687 | ||||
| Profit Margin | 0.15 % | ||||
| Operating Margin | 0.24 % | ||||
| Current Valuation | 138.84 B | ||||
| Shares Outstanding | 380.47 M | ||||
| Shares Owned By Insiders | 5.39 % | ||||
| Shares Owned By Institutions | 78.83 % | ||||
| Number Of Shares Shorted | 4.24 M | ||||
| Price To Earning | 63.07 X |
Currently Active Assets on Macroaxis
When determining whether Stryker is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Stryker Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Stryker Stock. Highlighted below are key reports to facilitate an investment decision about Stryker Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stryker. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. For more information on how to buy Stryker Stock please use our How to buy in Stryker Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Stryker Stock analysis
When running Stryker's price analysis, check to measure Stryker's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Stryker is operating at the current time. Most of Stryker's value examination focuses on studying past and present price action to predict the probability of Stryker's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Stryker's price. Additionally, you may evaluate how the addition of Stryker to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios |
Is Stryker's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stryker. If investors know Stryker will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stryker listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.027 | Dividend Share 3.05 | Earnings Share 8.24 | Revenue Per Share 53.999 | Quarterly Revenue Growth 0.118 |
The market value of Stryker is measured differently than its book value, which is the value of Stryker that is recorded on the company's balance sheet. Investors also form their own opinion of Stryker's value that differs from its market value or its book value, called intrinsic value, which is Stryker's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stryker's market value can be influenced by many factors that don't directly affect Stryker's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stryker's value and its price as these two are different measures arrived at by different means. Investors typically determine if Stryker is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stryker's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.